WO2011140334A3 - Compounds, methods of making or identifying compounds, and uses thereof - Google Patents

Compounds, methods of making or identifying compounds, and uses thereof Download PDF

Info

Publication number
WO2011140334A3
WO2011140334A3 PCT/US2011/035351 US2011035351W WO2011140334A3 WO 2011140334 A3 WO2011140334 A3 WO 2011140334A3 US 2011035351 W US2011035351 W US 2011035351W WO 2011140334 A3 WO2011140334 A3 WO 2011140334A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
making
identifying
identifying compounds
Prior art date
Application number
PCT/US2011/035351
Other languages
French (fr)
Other versions
WO2011140334A2 (en
Inventor
John A. Porco
Jerry Pelletier
Stephane P. Roche
Regina Cencic
Christina Rodrigo
Original Assignee
Trustees Of Boston University
Mcgill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Boston University, Mcgill University filed Critical Trustees Of Boston University
Publication of WO2011140334A2 publication Critical patent/WO2011140334A2/en
Publication of WO2011140334A3 publication Critical patent/WO2011140334A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides various compounds, compositions, and methods. In some embodiments, provided compounds have activity as, for example, inhibitors of protein translation.
PCT/US2011/035351 2010-05-06 2011-05-05 Compounds, methods of making or identifying compounds, and uses thereof WO2011140334A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33207910P 2010-05-06 2010-05-06
US61/332,079 2010-05-06

Publications (2)

Publication Number Publication Date
WO2011140334A2 WO2011140334A2 (en) 2011-11-10
WO2011140334A3 true WO2011140334A3 (en) 2012-03-08

Family

ID=44904477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035351 WO2011140334A2 (en) 2010-05-06 2011-05-05 Compounds, methods of making or identifying compounds, and uses thereof

Country Status (1)

Country Link
WO (1) WO2011140334A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
FI3888658T3 (en) 2015-11-25 2024-03-22 Effector Therapeutics Inc Eif4-a-inhibiting compounds and methods related thereto
KR20200123184A (en) 2018-02-19 2020-10-28 메모리얼 슬로안 케터링 캔서 센터 Substances and methods for treating hyperplasia disorder
CN115073407A (en) * 2021-03-10 2022-09-20 上海中医药大学 Medicinal composition with synthetic lethality and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181514A1 (en) * 2000-07-05 2003-09-25 Government Of The State Of Sarawak, Malaysia Therapeutic compounds and methods
WO2005092876A1 (en) * 2004-03-23 2005-10-06 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
WO2006007634A1 (en) * 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
WO2007139749A2 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181514A1 (en) * 2000-07-05 2003-09-25 Government Of The State Of Sarawak, Malaysia Therapeutic compounds and methods
WO2005092876A1 (en) * 2004-03-23 2005-10-06 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
WO2006007634A1 (en) * 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
WO2007139749A2 (en) * 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARBARA HAUSOTT ET AL.: "Flavaglines: A group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells", INTERNATIONAL JOURNAL OF CANCER, vol. 109, no. 6, 2004, pages 933 - 940, XP002515372, DOI: doi:10.1002/ijc.20033 *
REGINA CENCIC ET AL.: "Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol", PLOS ONE, vol. 4, no. 4, E52, 2009, pages 1 - 14, XP055219904, DOI: doi:10.1371/journal.pone.0005223 *

Also Published As

Publication number Publication date
WO2011140334A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2011047087A3 (en) Protein detection via nanoreporters
WO2010120757A3 (en) Regeneration of tissue without cell transplantation
MY160734A (en) Besylate salt of a btk inhibitor
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
WO2011072099A3 (en) Compositions and methods comprising protease variants
EP3329919A8 (en) Acc inhibitors and uses thereof
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
IN2012DN03883A (en)
WO2011130222A3 (en) Compositions and methods comprising variant proteases
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2007127834A3 (en) Compositions and methods of preparation thereof
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2012058211A3 (en) Quinazoline derivatives, compositions, and uses related thereto
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2011156654A3 (en) Pathways characterization of cells
WO2013185082A3 (en) Inhibitors of bruton's tyrosine kinase
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2009129497A3 (en) Methods and compositions for treating age-related macular degeneration
WO2012018932A3 (en) Compounds and compositions for mitigating tissue damage and lethality
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX2011013790A (en) Flavin derivatives.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778341

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11778341

Country of ref document: EP

Kind code of ref document: A2